RALEIGH, N.C., April 8 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces Dr. Andre van Vliet, Vice President of Medical Affairs - Early Development Services (EDS), will host an audio conference on the development of New Chemical Entities (NCEs) in the treatment of hepatitis C. This interactive session will take place on April 14, 2009 at 11:30 am (ET). Drawing on his 19 years of experience in this field, Dr. van Vliet will provide an inside look at opportunities and obstacles when developing a hepatitis C compound including critical steps to optimize the success potential of an NCE as well as pitfalls and obstacles.
Dr. Andre van Vliet is a Board Certified internist, with expertise and training in oncology and clinical Pharmacology. His published materials include a recent article for the American Gastroenterological Association Institute on hepatitis C. Since 1995, he has supervised all aspects of Phase I and IIa drug research for PRA’s EDS group.
With 228 beds in Europe and the U.S., and an innovative Phase I model that brings the center to the patients in Central/Eastern Europe, PRA’s EDS group provides comprehensive services for Phase I and Phase IIa studies. In the Netherlands, PRA EDS initiated the “Dutch Hepatitis Research Initiative.” In this unique research collaboration, PRA EDS collaborates with the Amsterdam Medical Centre and the Rotterdam Erasmus Medical Centre. In PRA’s Product Registration group (Phase II and III), over a third of its project management and clinical operations employees are experienced in infectious diseases clinical research.
The deadline for registration is Monday, April 13, 2009. To learn more about the audio conference, click http://www.prainternational.com/portal/page/portal/PRAINTL/News%20%20Events/Events/Popup. To register, clickhttp://www.fxconferences.com/Phase-I-Studies-with-Hepatitis-C-Compounds-in-Healthy-Volunteers-and-Patients-Views-from-Inside-P317.aspx
About PRA International
PRA International is a global Clinical Research Organization providing services through all phases of clinical development. Although we specialize in Infectious Diseases, Oncology, CNS, Respiratory/Allergy and Cardiovascular, we perform studies in all therapeutic areas. PRA has supported over 2,100 clinical trials through its 35 global offices. PRA’s therapeutic expertise, global reach and project experience, combined with extensive local knowledge, enable our project teams to deliver consistent and on time performance for our clients.
To learn more about PRA International, please visit http://www.prainternational.com, email endpoints@praintl.com or call our Global Headquarters at +1 (919) 786-8200.
CONTACT: Roger Boutin, Director of Marketing of PRA International, Inc.,
+1-434-951-3924
Web site: http://www.prainternational.com/
